Granules India Q1 Results FY27: Net Profit Rises 60% to Rs 180 Crore, Base Quarter Had a One-Time Loss

Granules India Q1 results FY27 were announced on Tuesday, 21 July 2026, with the company reporting the numbers summarised below on a consolidated basis for the quarter ended 30 June 2026.

Shares of Granules India fell 0.05 to Rs 875.70 on the NSE on the results day. The pharmaceutical ingredients and formulations maker posted a strong beat, though the year ago quarter carried a one-time charge that flatters the comparison.

Click Here – Get Free Investment Predictions

Granules India Q1 Results FY27 Key Takeaways

Here are the most important numbers from the June 2026 quarter at a glance.

• Revenue: Rs 1,476.8 Cr in Q1 FY27 versus Rs 1,210 Cr in Q1 FY26, up 22% year on year.
• EBITDA: Rs 338.9 Cr in Q1 FY27 versus Rs 246.6 Cr in Q1 FY26, up 37.4% year on year.
• Net Profit (PAT): Rs 180 Cr in Q1 FY27 versus Rs 112.6 Cr in Q1 FY26, up 60% year on year.
• Granules India share price fell 0.05 to Rs 875.70 on the NSE on the results day.

Granules India Q1 Results FY27 Financial Highlights

The table below summarises the consolidated numbers reported in the Granules India Q1 results FY27 against the year ago quarter.

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 1,476.8 Cr	Rs 1,210 Cr	+22%
EBITDA	Rs 338.9 Cr	Rs 246.6 Cr	+37.4%
Net Profit (PAT)	Rs 180 Cr	Rs 112.6 Cr	+60%

All figures are on a consolidated basis as reported for the quarter ended 30 June 2026. Tax expense stood at Rs 60.4 crore against Rs 31.9 crore in Q1 FY26.

Granules India Q1 Results FY27 Performance Analysis

Get Personalised Guidance from a SEBI-Registered Investment Advisor

An important qualifier applies to the Granules India Q1 results FY27: Q1 FY26 included a one-time loss of Rs 25.9 crore. Adjusting for that item, the underlying year on year profit growth, while still strong, would be more moderate than the headline 60% figure suggests.

Even accounting for the base effect, the operating numbers in the Granules India Q1 results FY27 are genuinely strong. Revenue grew 22% to Rs 1,476.8 crore and EBITDA grew faster at 37.4%, lifting the EBITDA margin to 22.9% from 20.4%, a clean sign of operating leverage in the active pharmaceutical ingredients and formulations business.

Tax expense nearly doubled to Rs 60.4 crore from Rs 31.9 crore in the Granules India Q1 results FY27, which is consistent with a company returning to a more normalised, higher taxable income base after the prior year’s one-time charge distorted the comparison.

Granules India Q1 Results FY27: Key Business Factors

1. Base Effect from the One-Time Charge

The Rs 25.9 crore one-time loss in Q1 FY26 inflates the headline 60% profit growth figure in the Granules India Q1 results FY27, and investors should look at the underlying operating trend rather than the reported growth rate alone.

2. Genuine Operating Leverage

Even adjusting for the base effect, EBITDA margin expanding to 22.9% from 20.4% on 22% revenue growth reflects real efficiency gains in the API and formulations business.

3. Normalising Tax Base

Tax expense nearly doubling to Rs 60.4 crore is consistent with the company returning to a normal taxable income trajectory after last year’s distortion.

Dividend Details

Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company’s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.

Granules India Q1 Results FY27 Outlook for the Full Year

After the Granules India Q1 results FY27, the September quarter will provide a cleaner year on year comparison without the prior year’s one-time item, making it the better gauge of the true underlying growth rate. Continued EBITDA margin expansion toward 23% or higher would be the key positive signal for FY27.

Granules India Stock Performance After the Q1 Results

Download the Univest iOS App or Univest Android App to track Granules India live share price and upcoming quarterly results.

Granules India share price fell 0.05 to Rs 875.70 on the NSE after the Granules India Q1 results FY27, as the market weighed the quarter’s numbers.

Investors can compare the trend of the counter with the Nifty 500 index to judge how the stock is placed relative to the broader market after the Granules India Q1 results FY27.

Key Risks

Investors going through the fine print of the Granules India Q1 results FY27 should also weigh the following risks.

1. Headline Growth Rate May Overstate the Trend

Because the Granules India Q1 results FY27 compare against a Q1 FY26 base with a one-time loss, the 60% profit growth headline should be read with that context rather than taken at face value.

2. API and Generic Pricing Pressure

The pharmaceutical ingredients business remains exposed to global pricing pressure on generic APIs and formulations, a structural industry risk.

3. Regulatory and Client Concentration Risk

As a bulk drug and API manufacturer, the company faces regulatory inspection risk at its facilities and some client concentration in key export markets.

Conclusion

Granules India Q1 results FY27 show net profit up 60% at Rs 180 crore and EBITDA margin expanding to 22.9%, but the comparison is flattered by a Rs 25.9 crore one-time loss in the Q1 FY26 base. The underlying operating trend remains genuinely positive. Investors should read the September quarter for a cleaner comparison and consult a SEBI-registered advisor before acting on the numbers.

Frequently Asked Questions on Granules India Q1 Results FY27

When were the Granules India Q1 results FY27 announced?

Ans. The Granules India Q1 results FY27 were announced on Tuesday, 21 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.

What is the PAT in the Granules India Q1 results FY27?

Ans. The consolidated PAT in the Granules India Q1 results FY27 stood at Rs 180 crore, up 60% from Rs 112.6 crore in Q1 FY26.

Why is the 60% profit growth in the Granules India Q1 FY27 results misleading?

Ans. The Granules India Q1 results FY27 show 60% growth, but the Q1 FY26 base included a one-time loss of Rs 25.9 crore, which inflates the reported growth rate. The underlying operating trend is positive but more moderate than the headline number suggests.

What was the revenue in the Granules India Q1 results FY27?

Ans. Revenue in the Granules India Q1 results FY27 stood at Rs 1,476.8 crore, up 22% from Rs 1,210 crore in Q1 FY26.

What was the EBITDA margin in the Granules India Q1 results FY27?

Ans. The EBITDA margin in the Granules India Q1 results FY27 expanded to 22.9% from 20.4% in Q1 FY26, with EBITDA up 37.4% to Rs 338.9 crore.

How did the share price react to the Granules India Q1 results FY27?

Ans. Granules India share price closed roughly flat, down 0.05% at Rs 875.70 on the NSE after the Granules India Q1 results FY27.

Is the stock a good buy after the Granules India Q1 results FY27?

Ans. The Granules India Q1 results FY27 show genuine operating improvement, but the headline growth rate is flattered by a prior year one-time item. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.

Where can I verify the Granules India Q1 results FY27?

Ans. The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.